Generic Medicine Info
Indications and Dosage
Adult: For mild to moderate pain: 2 g bid.

Osteoarthritis, Rheumatoid arthritis, Soft tissue rheumatism
Adult: 2 g bid. Max dose: 6 g daily.
Elderly: 2 g bid. Max dose: 4 g daily.
Should be taken with food. Take w/ or immediately after meals.
Previous or active peptic ulceration; child <16 yr except in Kawasaki syndrome, due to risk of Reye's syndrome; lactation, haemophilia and other bleeding disorders. Gout. Hypersensitivity.
Special Precautions
Asthma, allergic reactions, uncontrolled hypertension, hepatic or renal impairment, dehydration, alcohol dependence, febrile or viral infections. Pregnancy, elderly.
Adverse Reactions
Heartburn, GI disturbances, drowsiness and hypersensitivity reactions. Occasionally dizziness, tinnitus, and deafness.
In cases of overdosage, monitor plasma concentrations of salicylate and paracetamol.
Drug Interactions
Absorption may be reduced by colestyramine and kaolin; increased by domperidone and metoclopramide. Enhanced effects of coumarin, heparin, phenytoin and valproate; reduced effects of spironolactone and sulfinpyrazone. Risk of side effects increased and hypotensive effect antagonized by ACE inhibitors and angiotensin-2 receptor antagonists; carbonic anhydrase inibitors, clopidogrel, corticosteroids, coumarin, phenindione, sibutramine and venlafaxine. Caution when using concurrently with cilostazol, mifepristone or other NSAIDs.
Mechanism of Action: Benorilate is an aspirin-paracetamol ester with analgesic, anti-inflammatory and antipyretic properties. It is used in the treatment of mild to moderate pain and fever.
Metabolism: Rapidly metabolised to salicylate and paracetamol after absorption.
MIMS Class
Analgesics (Non-Opioid) & Antipyretics
Disclaimer: This information is independently developed by MIMS based on Benorilate from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2024 MIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in